Do analysts prefer AVIR or CMPS?

Compass Pathways has a consensus target price of $23.36, indicating a potential upside of 72.50%. Given Compass Pathways' stronger consensus rating and higher possible upside, analysts clearly believe Compass Pathways is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Compass Pathways 1 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.88

Which has higher valuation and earnings, AVIR or CMPS?

Compass Pathways is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A Compass Pathways N/A N/A -$287.86M -$4.62 N/A

Is AVIR or CMPS more profitable?

Compass Pathways' return on equity of -49.63% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -57.01% -51.49% Compass Pathways N/A -49.63% -13.08%

Does the media favor AVIR or CMPS?

In the previous week, Compass Pathways had 13 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 15 mentions for Compass Pathways and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.78 beat Compass Pathways' score of 0.38 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compass Pathways 4 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate AVIR or SEPN?

Septerna has a consensus price target of $45.89, suggesting a potential upside of 18.18%. Given Septerna's stronger consensus rating and higher possible upside, analysts plainly believe Septerna is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Septerna 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.82

Does the media refer more to AVIR or SEPN?

In the previous week, Septerna had 5 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 7 mentions for Septerna and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.78 beat Septerna's score of 0.53 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Septerna 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend AVIR or NTLA?

Intellia Therapeutics has a consensus target price of $20.85, suggesting a potential upside of 74.66%. Given Intellia Therapeutics' higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Intellia Therapeutics 4 Sell rating(s) 8 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.35

Does the media favor AVIR or NTLA?

In the previous week, Intellia Therapeutics had 20 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 22 mentions for Intellia Therapeutics and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.78 beat Intellia Therapeutics' score of -0.05 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate VIR or AVIR?

Vir Biotechnology currently has a consensus target price of $20.63, indicating a potential upside of 133.84%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, equities research analysts plainly believe Vir Biotechnology is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vir Biotechnology 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Does the media prefer VIR or AVIR?

In the previous week, Vir Biotechnology had 11 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 13 mentions for Vir Biotechnology and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.78 beat Vir Biotechnology's score of 0.33 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Atea Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate AVIR or XNCR?

Xencor has a consensus price target of $24.86, indicating a potential upside of 19.45%. Given Xencor's higher probable upside, analysts plainly believe Xencor is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Xencor 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.44

Does the media refer more to AVIR or XNCR?

In the previous week, Xencor had 15 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 17 mentions for Xencor and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.78 beat Xencor's score of 0.52 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xencor 4 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Atea Pharmaceuticals (AVIR) Competitors

$5.25 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$5.08 -0.17 (-3.24%)

As of 08/7/2026 07:34 PM Eastern

Compare

AVIR vs. CMPS, SEPN, NTLA, VIR, and XNCR

Should you buy Atea Pharmaceuticals stock or one of its competitors? MarketBeat compares Atea Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atea Pharmaceuticals include Compass Pathways (CMPS), Septerna (SEPN), Intellia Therapeutics (NTLA), Vir Biotechnology (VIR), and Xencor (XNCR).

How does Atea Pharmaceuticals compare to Compass Pathways?

Atea Pharmaceuticals (NASDAQ:AVIR) and Compass Pathways (NASDAQ:CMPS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.2% of Compass Pathways shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Comparatively, 2.8% of Compass Pathways shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Compass Pathways is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

Compass Pathways has a consensus target price of $23.36, indicating a potential upside of 72.50%. Given Compass Pathways' stronger consensus rating and higher possible upside, analysts clearly believe Compass Pathways is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

Compass Pathways' return on equity of -49.63% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Compass Pathways	N/A	-49.63%	-13.08%

Atea Pharmaceuticals has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market.

In the previous week, Compass Pathways had 13 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 15 mentions for Compass Pathways and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.78 beat Compass Pathways' score of 0.38 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compass Pathways	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Compass Pathways beats Atea Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Septerna?

Atea Pharmaceuticals (NASDAQ:AVIR) and Septerna (NASDAQ:SEPN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Septerna has higher revenue and earnings than Atea Pharmaceuticals. Septerna is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Septerna	$45.95M	38.09	-$48.88M	-$0.81	N/A

Septerna has a consensus price target of $45.89, suggesting a potential upside of 18.18%. Given Septerna's stronger consensus rating and higher possible upside, analysts plainly believe Septerna is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Atea Pharmaceuticals has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, Septerna has a beta of 2.29, meaning that its share price is 129% more volatile than the broader market.

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Comparatively, 5.8% of Septerna shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Atea Pharmaceuticals has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Septerna	-49.88%	-12.72%	-8.87%

In the previous week, Septerna had 5 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 7 mentions for Septerna and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.78 beat Septerna's score of 0.53 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Septerna	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Septerna beats Atea Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Intellia Therapeutics?

Atea Pharmaceuticals (NASDAQ:AVIR) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 21.6% of Atea Pharmaceuticals shares are held by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Atea Pharmaceuticals has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market.

Intellia Therapeutics has a consensus target price of $20.85, suggesting a potential upside of 74.66%. Given Intellia Therapeutics' higher probable upside, analysts plainly believe Intellia Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35

Atea Pharmaceuticals has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -672.16%. Atea Pharmaceuticals' return on equity of -57.01% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

In the previous week, Intellia Therapeutics had 20 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 22 mentions for Intellia Therapeutics and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.78 beat Intellia Therapeutics' score of -0.05 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Atea Pharmaceuticals has higher earnings, but lower revenue than Intellia Therapeutics. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Intellia Therapeutics	$67.67M	24.65	-$412.69M	-$3.36	N/A

Summary

Atea Pharmaceuticals beats Intellia Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

Vir Biotechnology has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

Vir Biotechnology currently has a consensus target price of $20.63, indicating a potential upside of 133.84%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, equities research analysts plainly believe Vir Biotechnology is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 2.9% of Vir Biotechnology shares are held by company insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Atea Pharmaceuticals has lower revenue, but higher earnings than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	21.77	-$437.99M	-$1.86	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

In the previous week, Vir Biotechnology had 11 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 13 mentions for Vir Biotechnology and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.78 beat Vir Biotechnology's score of 0.33 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Atea Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Atea Pharmaceuticals has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -29.99% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-638.88%	-29.99%	-23.62%
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

Summary

Vir Biotechnology beats Atea Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Xencor?

Atea Pharmaceuticals (NASDAQ:AVIR) and Xencor (NASDAQ:XNCR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Xencor has higher revenue and earnings than Atea Pharmaceuticals. Xencor is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Xencor	$125.58M	12.32	-$91.92M	-$2.17	N/A

Atea Pharmaceuticals has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market. Comparatively, Xencor has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 5.1% of Xencor shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Xencor has a consensus price target of $24.86, indicating a potential upside of 19.45%. Given Xencor's higher probable upside, analysts plainly believe Xencor is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Xencor	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

In the previous week, Xencor had 15 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 17 mentions for Xencor and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.78 beat Xencor's score of 0.52 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Xencor	4 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Atea Pharmaceuticals has a net margin of 0.00% compared to Xencor's net margin of -155.59%. Xencor's return on equity of -28.66% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Xencor	-155.59%	-28.66%	-20.38%

Summary

Atea Pharmaceuticals and Xencor tied by winning 8 of the 16 factors compared between the two stocks.

Get Atea Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVIR vs. The Competition

Export

Metric	Atea Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$420.16M	$11.85B	$7.00B	$12.99B
Dividend Yield	N/A	2.70%	2.58%	10.20%
P/E Ratio	-2.49	790.97	270.58	25.05
Price / Sales	N/A	739.94	598.42	84.08
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	1.49	10.29	11.18	6.43
Net Income	-$158.35M	$2.78B	$3.45B	$348.10M
7 Day Performance	13.88%	2.76%	3.37%	2.66%
1 Month Performance	5.21%	-0.65%	-0.73%	-0.85%
1 Year Performance	55.33%	192.52%	77.30%	23.96%

Atea Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVIR Atea Pharmaceuticals	0.9477 of 5 stars	$5.25 flat	N/A	+55.3%	$420.16M	N/A	N/A	70	Upcoming Earnings
CMPS Compass Pathways	3.0092 of 5 stars	$10.85 -3.7%	$23.36 +115.3%	+208.4%	$1.52B	N/A	N/A	120	Earnings Report Analyst Forecast
SEPN Septerna	2.0778 of 5 stars	$33.97 +1.4%	$45.89 +35.1%	+232.2%	$1.51B	$45.95M	N/A	N/A	Gap Up
NTLA Intellia Therapeutics	3.2434 of 5 stars	$10.89 +2.1%	$20.19 +85.4%	+10.7%	$1.49B	$67.67M	N/A	600	Trending News Earnings Report Analyst Upgrade Analyst Revision
VIR Vir Biotechnology	2.3689 of 5 stars	$8.85 +0.6%	$20.88 +135.9%	+105.1%	$1.48B	$68.56M	N/A	580	Earnings Report Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVIR) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atea Pharmaceuticals (AVIR) Competitors

AVIR vs. CMPS, SEPN, NTLA, VIR, and XNCR

How does Atea Pharmaceuticals compare to Compass Pathways?

Summary

How does Atea Pharmaceuticals compare to Septerna?

Summary

How does Atea Pharmaceuticals compare to Intellia Therapeutics?

Summary

How does Atea Pharmaceuticals compare to Vir Biotechnology?

Summary

How does Atea Pharmaceuticals compare to Xencor?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVIR vs. The Competition

Atea Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atea Pharmaceuticals (AVIR) Competitors

AVIR vs. CMPS, SEPN, NTLA, VIR, and XNCR

How does Atea Pharmaceuticals compare to Compass Pathways?

Do institutionals and insiders believe in AVIR or CMPS?

Which has higher valuation and earnings, AVIR or CMPS?

Do analysts prefer AVIR or CMPS?

Is AVIR or CMPS more profitable?

Which has more risk & volatility, AVIR or CMPS?

Does the media favor AVIR or CMPS?

Summary

How does Atea Pharmaceuticals compare to Septerna?

Which has stronger valuation & earnings, AVIR or SEPN?

Do analysts rate AVIR or SEPN?

Which has more risk & volatility, AVIR or SEPN?

Do institutionals & insiders hold more shares of AVIR or SEPN?

Is AVIR or SEPN more profitable?

Does the media refer more to AVIR or SEPN?

Summary

How does Atea Pharmaceuticals compare to Intellia Therapeutics?

Do institutionals & insiders have more ownership in AVIR or NTLA?

Which has more volatility and risk, AVIR or NTLA?

Do analysts recommend AVIR or NTLA?

Is AVIR or NTLA more profitable?

Does the media favor AVIR or NTLA?

Which has better earnings and valuation, AVIR or NTLA?

Summary

How does Atea Pharmaceuticals compare to Vir Biotechnology?

Which has more risk & volatility, VIR or AVIR?

Do analysts rate VIR or AVIR?

Do institutionals & insiders believe in VIR or AVIR?

Which has stronger earnings and valuation, VIR or AVIR?

Does the media prefer VIR or AVIR?

Is VIR or AVIR more profitable?

Summary

How does Atea Pharmaceuticals compare to Xencor?

Which has better valuation and earnings, AVIR or XNCR?

Which has more volatility and risk, AVIR or XNCR?

Do insiders and institutionals hold more shares of AVIR or XNCR?

Do analysts rate AVIR or XNCR?

Does the media refer more to AVIR or XNCR?

Is AVIR or XNCR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVIR vs. The Competition

Atea Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools